From: The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinoma—differences in histological subtypes
Age at surgery (y): | ||
---|---|---|
Median/range: | 66/34–82 | |
n = 175 | % | |
Sex: | ||
Male: | 95 | 54.3 |
Female: | 80 | 45.7 |
Smoking history: | ||
Current: | 107 | 61.1 |
Former: | 57 | 32.6 |
Never: | 11 | 6.3 |
Weight loss: | ||
No weight loss: | 48 | 27.4 |
Weight loss < 10 % | 99 | 56.6 |
Weight loss ≥ 10 % | 22 | 12.6 |
No data: | 6 | 3.4 |
Tumor size: | ||
< 3 cm | 99 | 56.6 |
> 3 cm - ≤5 cm | 55 | 31.4 |
> 5 cm- ≤7 cm | 19 | 10.9 |
> 7 cm | 2 | 1.1 |
Stage: | ||
I: | 97 | 55.4 |
II: | 55 | 31.4 |
IIIa: | 23 | 13.1 |
Histology: | ||
Adenocarcinoma: | 99 | 56.6 |
Squamous cell carcinoma: | 44 | 25.1 |
Other: | 32 | 18.3 |
EGFR: | ||
EGFR mutated: | 13 | 7.4 |
EGFR not mutated: | 159 | 90.9 |
EGFR not tested: | 3 | 1.7 |
Chemotherapy: | ||
Adjuvant chemotherapy: | 54 | 30.9 |
Neoadjuvant chemotherapy: | 3 | 1.7 |
No chemotherapy: | 116 | 66.3 |
No data: | 2 | 1.1 |
Radiotherapy: | ||
Adjuvant or neoadjuvant: | 9 | 5.1 |
No radiotherapy | 166 | 94.9 |
Status at 5 year follow up: | ||
Alive with no disease: | 81 | 46.3 |
Alive with disease: | 8 | 4.6 |
Dead: | 86 | 49.1 |
Cause of death (n = 86): | ||
Lung cancer: | 48 | 55.8 |
Cardiovascular disease: | 15 | 17.4 |
Other: | 23 | 26.7 |